Amarin | AMRN - Capital Ordinaire





Capital Ordinaire Changement Date
AbbVie USD 1.77B 1.75B 2025-06
Alnylam Pharmaceuticals USD 133.44M 1.07M 2026-03
Amarin USD 20.81M 13K 2025-12
AstraZeneca USD 1.55B 73K 2026-03
BioCryst Pharmaceuticals USD 213.06M 2.54M 2025-12
DBV Technologies USD 136.82M 51.98K 2025-09
Esperion Therapeutics USD 245.22M 39.79M 2025-12
GlaxoSmithKline GBP 4.05B 20.6M 2026-03
Halozyme Therapeutics USD 117.78M 259K 2025-12
Heron Therapeutics USD 188.31M 4.99M 2025-12
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
Nektar Therapeutics USD 20.38M 20.36M 2025-12
Neurocrine Biosciences USD 100.1M 400K 2025-12
Novartis USD 1.91B 60K 2026-03